Jaguar Health, Inc. (NASDAQ:JAGX) | Finanzwire

Basculer en Français

11005	Companies
241105	Keywords
169688	Articles
129790	Press releases

Home
Companies
Jaguar Health, Inc.

BRIEF

published on 09/23/2025 at 15:05, 11 months 23 days ago

Jaguar Health to Present at Key Conferences in September 2025

Jaguar Health Plant-based Medicines FDA-approved Drug Virtual Conferences Gastrointestinal Treatments
PRESS RELEASE

published on 09/23/2025 at 15:00, 11 months 23 days ago

Jaguar Health Presenting September 25 at Emerging Growth Conference and September 30 at Lytham Partners Fall 2025 Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. announces CEO Lisa Conte's virtual presentations at upcoming conferences. The company focuses on developing plant-derived medicines for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Jaguar Health Lisa Conte Virtual Presentations
BRIEF

published on 09/05/2025 at 15:05, 1 year ago

Jaguar Health to Present at H.C. Wainwright Global Investment Conference

Pharmaceuticals Jaguar Health Conference Presentation H.C. Wainwright Gastrointestinal Health
PRESS RELEASE

published on 09/05/2025 at 15:00, 1 year ago

Jaguar Health Presenting at September 8-10 H.C. Wainwright Annual Global Investment Conference to Provide Updates on Near-Term Catalysts
Jaguar Health, Inc. to present at H.C. Wainwright 27th Annual Global Investment Conference. Lisa Conte to discuss pharmaceutical developments for gastrointestinal distress

Pharmaceuticals Gastrointestinal Distress Lisa Conte Jaguar Health Inc. H.C. Wainwright Conference
BRIEF

published on 08/21/2025 at 15:05, 1 year ago

Jaguar Health Targets Global Expansion for Canalevia®

FDA Approval Jaguar Health Canalevia Dog Diarrhea Treatment Animal Health Summit
PRESS RELEASE

published on 08/21/2025 at 15:00, 1 year ago

Jaguar Health Participating in August 25-26 Animal Health Summit with Goal of Securing Collaboration to Expand Canalevia's Indication to Treatment of General Diarrhea in Dogs
Jaguar Health announces conditional FDA approval of Canalevia-CA1 for CID in dogs and strategic plans to expand indication for general diarrhea treatment globally. Participation in 2025 Animal Health Summit

FDA Approval Canalevia-CA1 Partnerships Animal Health Diarrhea Treatment
BRIEF

published on 08/19/2025 at 22:20, 1 year ago

Jaguar Health Announces Approval of All Proposals at Annual Meeting

Crofelemer FDA Approval Jaguar Health Annual Meeting Partnership Strategy
PRESS RELEASE

published on 08/19/2025 at 22:15, 1 year ago

Jaguar Health Reports Approval of All Proposals at August 2025 Annual Meeting of Stockholders
Jaguar CEO Lisa Conte to provide updates on crofelemer trial results and regulatory pathway at Emerging Growth Conference. Annual meeting results and company strategy also discussed

Crofelemer Jaguar Health Lisa Conte Emerging Growth Conference Regulatory Pathway
BRIEF

published on 08/19/2025 at 15:05, 1 year ago

Jaguar Health's Napo Pharmaceuticals Seeks FDA Guidance on Crofelemer for Rare Pediatric Disease

Napo Pharmaceuticals Jaguar Health Crofelemer Trials FDA Meeting MVID Treatment
PRESS RELEASE

published on 08/19/2025 at 15:00, 1 year ago

Jaguar Health Family Company Napo Pharmaceuticals to Meet with FDA to Discuss Potential Regulatory Pathways for Crofelemer for Treatment of Ultrarare Pediatric Indication Microvillus Inclusion Disease (MVID)
Napo Pharmaceuticals plans FDA meeting to discuss crofelemer clinical program for MVID, with proof-of-concept results reducing TPN. Abstract accepted for NASPGHAN 2025 Annual Meeting in Chicago

Napo Pharmaceuticals Crofelemer MVID FDA Meeting NASPGHAN 2025 Annual Meeting

Accesswire

Published on 09/16/2026 at 16:55, 4 hours 21 minutes ago

CORRECTION FROM SOURCE: SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project
Published on 09/16/2026 at 15:00, 6 hours 16 minutes ago

2026 Canada's Top 40 Under 40(R) Honourees Announced
Published on 09/16/2026 at 14:00, 7 hours 16 minutes ago

Ameriwest Awaits Bornite Core Assay Results and Provides Q3 2026 Corporate Update
Published on 09/16/2026 at 13:30, 7 hours 46 minutes ago

Sterling Extends Core MEPS Copper Zone to 700m; Intersects 200m of 0.53% CuEq Including 102m of 0.81% CuEq
Published on 09/16/2026 at 13:23, 7 hours 53 minutes ago

SLAM Reports 1.60% Copper Equivalent Over 14.45 Meters in Hole GW26-33; Trenching Gold-Antimony Targets on Moose Lake Project

View all ACCESSWIRE

EQS Group

Published on 09/16/2026 at 20:27, 48 minutes ago

EQS-Adhoc: REPLOID Group AG resolves to issue convertible notes in an aggregate principal amount of up to EUR 30 million
Published on 09/16/2026 at 19:05, 2 hours 11 minutes ago

EcoFlow to showcase its open home energy ecosystem at Solar & Storage Live Zurich 2026
Published on 09/16/2026 at 18:22, 2 hours 54 minutes ago

EQS-Adhoc: elumeo SE resolves on a capital increase against cash contributions, ex-cluding pre-emptive rights, and a move to the Scale segment
Published on 09/16/2026 at 18:11, 3 hours 4 minutes ago

EQS-Adhoc: Berentzen-Gruppe Aktiengesellschaft confirms rumours regarding negotiations on a voluntary takeover offer by SAZERAC COMPANY, INC.
Published on 09/16/2026 at 18:05, 3 hours 11 minutes ago

LawZero receives a commitment of up to $300M in joint funding from Canada and Germany

Les Echos

Published on 09/16/2026 at 20:46, 30 minutes ago

LNA SANTE : 2026 First Half Results
Published on 09/16/2026 at 17:45, 3 hours 31 minutes ago

5th edition of “On the way up” show
Published on 09/16/2026 at 17:45, 3 hours 31 minutes ago

Report on share repurchases from 9 to 15 September 2026
Published on 09/16/2026 at 07:00, 14 hours 16 minutes ago

bioMérieux Receives IVDR Class D CE Marking for BIOFIRE® Respiratory 2.1 plus Panel and BIOFIRE® FILMARRAY® Pneumonia plus Panel, the first syndromic tests including MERS-CoV to achieve this certification
Published on 09/15/2026 at 18:00, 1 day 3 hours ago

Report on the Combined General Meeting of the 10th of September 2026

View all LES ECHOS COMFI WIRE